Compare PDFS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDFS | NVAX |
|---|---|---|
| Founded | 1992 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | PDFS | NVAX |
|---|---|---|
| Price | $28.81 | $6.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | ★ $34.50 | $9.75 |
| AVG Volume (30 Days) | 299.3K | ★ 3.3M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | $206,706,000.00 | ★ $1,064,651,000.00 |
| Revenue This Year | $24.45 | $58.91 |
| Revenue Next Year | $18.83 | N/A |
| P/E Ratio | ★ N/A | $3.33 |
| Revenue Growth | ★ 21.23 | 20.27 |
| 52 Week Low | $15.91 | $5.01 |
| 52 Week High | $32.31 | $11.55 |
| Indicator | PDFS | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 47.26 |
| Support Level | $27.12 | $6.36 |
| Resistance Level | $29.25 | $6.98 |
| Average True Range (ATR) | 1.19 | 0.22 |
| MACD | -0.24 | 0.06 |
| Stochastic Oscillator | 33.14 | 63.48 |
PDF Solutions Inc offers products and services designed to empower engineers and data scientists across the semiconductor ecosystem to improve the yield, quality, and profitability of their products. The solutions combine proprietary software, physical intellectual property (or IP) for integrated circuit (or IC) designs, electrical measurement hardware tools, various methodologies, and professional services. The company's products and services are sold to integrated device manufacturers (or IDMs), fabless semiconductor companies, foundries, outsourced semiconductor assembly and test (or OSATs), and system houses.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.